1. Olivier-Gougenheim, L. et al. Invasive fungal infections in immunocompromised children: novel insight following a national study. J. Pediatr.-US. https://doi.org/10.1016/j.jpeds.2021.05.016 (2021).
2. Mueller, S. W. et al. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert. Opin. Pharmacol. 4, 11–17 (2021).
3. Nweze, E. I. & Ogbonnaya, U. L. Oral Candida isolates among HIV-infected subjects in Nigeria. J. Microbiol. Immunol. 44, 172–177 (2012).
4. Nejat, Z. A., Farahyar, S., Falahati, M., Khozani, M. A. & Hashemi-Hafshenjani, S. Molecular identification and antifungal susceptibility pattern of non-albicans Candida species isolated from vulvovaginal candidiasis. Iran Biomed. J. 22, 33–41 (2018).
5. Wu, P. F., Liu, W. L., Hsieh, M. H., Hii, I. M. & Wang, F. D. Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients. Emerg. Microbes Infect. 6, e87 (2017).